ArticleFrontiers in immunology2017
A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens,
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- CRISPR Engineering of Bacteriophage T4 to Design Vaccines Against SARS-CoV-2 and Emerging Pathogens.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Biodefence research two decades on: worth the investment?The Lancet. Infectious diseases · 2021Review
- Harnessing Clinical Trial Capacity to Mitigate Zoonotic Diseases: The Role of Expert Scientists in Ethiopia.Frontiers in public health · 2021Article
- Current Status and Trends in Prophylaxis and Management of Anthrax Disease.Pathogens (Basel, Switzerland) · 2020Review
- Deliberate release: Plague - A review.Journal of biosafety and biosecurity · 2020Review
- Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.Acta biomaterialia · 2019Article
- Animal Models of Type III Secretion System-Mediated Pathogenesis.Pathogens (Basel, Switzerland) · 2019Review
- Crystal structure of UDP-glucose pyrophosphorylase from Yersinia pestis, a potential therapeutic target against plague.Acta crystallographica. Section F, Structural biology communications · 2019Article
- A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells.Science advances · 2019Article
- Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.PLoS neglected tropical diseases · 2019Article
- Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.Advanced drug delivery reviews · 2019Review
- Plague vaccine: recent progress and prospects.NPJ vaccines · 2019Review
- Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.The Lancet. Infectious diseases · 2019Review
- Article
- Antibody-based vaccine strategies against intracellular pathogens.Current opinion in immunology · 2018Review
- Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Bioterrorism remains as one of the biggest challenges to global security and public health. Since the deadly anthrax attacks of 2001 in the United States,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.